In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC)

CourtDistrict Court, D. Minnesota
DecidedApril 2, 2018
Docket0:17-cv-01884
StatusUnknown

This text of In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC) (In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC)) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC), (mnd 2018).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MINNESOTA ______________________________________________________________________________

Elan Klein, Adam Klein, Leah Weaver, and Case No. 17-cv-1884 (PAM/SER) Arissa Paschalidis,

Plaintiffs, v. ORDER

Prime Therapeutics, LLC, Express Scripts, Inc., Express Scripts Holding Company, CVS Health Corporation, Medco Health Solutions, Inc., Caremark, L.L.C., Caremark Rx, L.L.C., and CaremarkPCS Health, L.L.C.,

Defendants.

Kathleen M. Donovan-Maher, Esq., Berman Tabacco, Boston, Massachusetts, for Plaintiffs.

Kristen G. Marttila, Esq., Lockridge Grindal Nauen, P.L.L.P, Minneapolis, Minnesota, for Plaintiffs.

Jaime Stilson, Esq., Dorsey & Whitney LLP, Minneapolis, Minnesota, for Defendant Prime Therapeutics.

Jessica J. Nelson, Esq., Felhaber Larson, Minneapolis, Minnesota, for Defendant Express Scripts.

Daniel M. Dockery, Esq., Williams & Connolly, LLP, Washington, DC, for Defendant CVS, Medco Health, and Caremark.

Steven L. Severson, Esq., Faegre Baker Daniels LLP, Minneapolis, Minnesota, for Defendants.

STEVEN E. RAU, United States Magistrate Judge This matter comes before the undersigned on Defendants Express Scripts Inc., Express Scripts Holding Co., and Medco Health Solution, Inc.’s (collectively, “Express Scripts”) Motion for Further Consideration of Sealing [Doc. No. 154], Defendant Prime Therapeutic LLC’s (“Prime”) Motion for Further Consideration of Sealing [Doc. No. 160], and Defendants CVS Health Corporation, Caremark, L.L.C., Caremark RX, L.L.C., and CaremarkPCS Health, L.L.C.’s (collectively, “CVS”) Motion for Further Consideration of Sealing [Doc. No. 166] (collectively, “Motions for Continued Sealing”). This matter was referred to the undersigned

pursuant to 28 U.S.C. § 636 and District of Minnesota Local Rule 72.1. For the reasons stated below, the Court grants Defendants’ Motions for Continued Sealing. I. BACKGROUND The underlying litigation involves Plaintiffs Elan Klein, Adam Klein, Leah Weaver, and Arissa Paschalidis’s (collectively, “Plaintiffs”) allegations that Defendants, pharmacy benefit managers (“PBMs”), violated the Employee Retirement Income Security Act of 1974 (“ERISA”) in the manner in which the Defendants negotiated out-of-pocket costs for EpiPens for individuals covered by the Defendants’ health plans.1 See generally (Am. Compl.) [Doc. No. 107]. Currently before the Court are Defendants’ Motions for Further Consideration of Sealing regarding Document Numbers 53, 58, 59, 60, 61, 63, 67, 70, 71, 74, 75, 76, 81, 84, originally filed under

seal in support of the Defendants’ respective Motions to Dismiss [Doc. No. 51, 56, 79]. The Motions to Dismiss were vacated as part of the Court’s Order granting Plaintiffs’ leave to file an amended complaint. See (Order Dated Aug. 24, 2017) [Doc. No. 94]. Plaintiffs filed their Amended Complaint on September 27, 2017, and Defendants renewed their respective motions to dismiss [Doc. Nos. 142, 145, 149]. Defendants renewed motions to dismiss are still pending and no memorandum or supporting documents have yet been filed on these motions to dismiss.2

1 The Defendants’ Motions for Continued Sealing were filed before the cases 17-cv-1884, 17-cv-5154, and 18-cv-18 were consolidated adding additional plaintiffs and defendants. See (Order Dated Feb. 1, 2018) [Doc. No. 190] (consolidating cases). 2 The Court does not expect that supporting documents will be filed for these motions to dismiss; these motions to dismiss are likely moot in light of consolidation that has occurred in As required under the Local Rules, the parties first submitted a Joint Motion Regarding Continued Sealing (“Joint Motion”) [Doc. No. 115]. The parties agreed that the listed documents should remain sealed, but disagreed as to why. See generally (Joint Mot.). In particular, the Defendants asserted the documents in question contained proprietary business information. See

generally (id.). Three entries in the Joint Motion specified that certain nonparties considered specific documents confidential. See (id. at 8–10). The remaining entries in the Joint Motion did not include an affirmative statement that a nonparty considered the document confidential. See (id. at 1–7, 11–17). Plaintiffs did not concede that the information Defendants wanted to seal was proprietary, but given the fact that the underlying motion has been mooted by Plaintiffs’ filing of an Amended Complaint on September 27, 2017, the public’s interest in a common-law right of access is minimal, and an in-depth analysis of Defendants’ confidentiality claims are not warranted in light of the efficiency considerations embodied in Rule 1.

See, e.g., (id. at 2–3). The Court denied the parties’ Joint Motion. (Text Only Order Dated October 27, 2017) [Doc. No. 153]. The Defendants’ filed their respective Motions for Continued Sealing and memoranda in support and Plaintiffs filed an omnibus opposition brief thereafter. See (Mots. for Continued Sealing); (Defs.’ Express Scripts Inc., Express Scripts Holding Company, & Medco Health Solution, Inc.’s Mem. of Law in Supp. of Mot. for Further Consideration of Sealing, “Express Scripts’ Mem. in Supp.”) [Doc. No. 156]; (Def. Prime Therapeutics LLC’s Mem. in Supp. of its Mot. for Further Consideration of Sealing, “Prime’s Mem. in Supp.”) [Doc. No. 162]; (Mem. in Supp. of Defs. CVS Health Corporation, Caremark,

this case. Specifically, the Honorable Paul Magnuson ordered Plaintiffs to file a Consolidated Complaint with plaintiffs in case numbers 17-cv-5154 and 18-cv-18 on or before April 2, 2018, and the consolidated Defendants may move to dismiss within 60 days of the filing of the Consolidated Complaint. See (Order Dated Feb. 1, 2018) [Doc. No. 190]; see also Pure Country, Inc. v. Sigma Chi Fraternity, 312 F.3d 952, 956 (8th Cir. 2002) (stating the filing of an amended complaint may render moot a motion to dismiss the original complaint). L.L.C, Caremark RX, L.L.C., & CaremarkPCS Health, L.L.C.’s Mot. for Further Consideration of Sealing, “CVS’s Mem. in Supp.”) [Doc. No. 168]; (Pls.’ Omnibus Mem. of Law in Opp’n to Defs.’ Mots. for Further Consideration of Sealing, “Pls.’ Mem. in Opp’n”) [Doc. No. 173]. Defendants argue generally that the documents should remain sealed because to the

extent they are judicial records, the information they seek to seal is highly confidential and the public interest is minimal and outweighed by their respective interests in nondisclosure. See (Express Scripts’ Mem. in Supp. at 7–11); (Prime’s Mem. in Supp. at 6–11, 21); (CVS’s Mem. in Supp. at 6–11). Prime also argues that to the extent the documents are not judicial records, they have established good cause under Rule 26 of the Federal Rules of Civil Procedure for the documents continued sealing. See (Prime’s Mem. in Supp. at 12–20). Oral argument was heard by the undersigned and the matter is fully briefed and ripe for consideration. See (Minute Entry Dated Jan 23, 2018) [Doc. No. 186]. II. DISCUSSION A. Legal Standard

“There is a common law right of access to judicial records, which includes the public’s right to access documents that are submitted to the Court and that form the basis for judicial decisions.” Skky, LLC v. Facebook, Inc., 191 F. Supp. 3d 977, 980 (D. Minn. 2016) (Wright, J.) (internal quotation marks omitted).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
In re EpiPen ERISA Litigation (Klein v. Prime Therapeutics, LLC), Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-epipen-erisa-litigation-klein-v-prime-therapeutics-llc-mnd-2018.